共 43 条
[1]
Ullah F., Malik S.A., Ahmed J., Antibiotic susceptibility pattern and ESBL prevalence in nosocomial Escherichia coli from urinary tract infections in Pakistan, Afr J Biotechnol, 8, 16, pp. 3921-3926, (2009)
[2]
Cox C.E., Nosocomial urinary tract infections, Urol, 32, 3, pp. 210-215, (1988)
[3]
Gonzalez C.M., Schaeffer A.J., Treatment of urinary tract infection: What's old, what's new, and what works, World J Urol, 17, 6, pp. 372-382, (1999)
[4]
Coque T.M., Baquero F., Canton R., Increasing prevalence of ESBL producing enterobacteriaceae in Europe, Eurosurveillance, 13, 47, pp. 1-11, (2008)
[5]
Paterson D.L., Bonomo R.A., Extended-spectrum β-lactamases: A clinical update, Clinical Microbiology Reviews, 18, 4, pp. 657-686, (2005)
[6]
Bradford P.A., Extended-spectrum β-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat, Clinical Microbiology Reviews, 14, 4, pp. 933-951, (2001)
[7]
Jacoby G.A., Munoz-Price L.S., The new beta-lactamases, New Engl J Med, 352, 4, pp. 380-391, (2005)
[8]
Rupp M.E., Fey P.D., Extended spectrum β-lactamase (ESBL)-producing enterobacteriaceae: Considerations for diagnosis, prevention and drug treatment, Drugs, 63, 4, pp. 353-365, (2003)
[9]
Meyer K.S., Urban C., Eagan J.A., Berger B.J., Rahal J.J., Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins, Annals of Internal Medicine, 119, 5, pp. 353-358, (1993)
[10]
Naumovsky L., Quinn J.P., Miyashiro D., Patel M., Bush K., Singer S.B., Outbreak of ceftazidime resistance due to a novel extended spectrum β-lactamase in isolates from cancer patients, Antimicrob Agents Chemother, 36, pp. 1991-1996, (1992)